Get the latest tech news

US approves "milestone" Parkinson's treatment for 2025 release

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease. The US FDA this week approved the sale of the treatment, which harnesses innovative technology to make managing the condition easier and more impactful, will be available…

"The approval of Onapgo (SPN-830) is a significant milestone in Parkinson’s disease management," Kelly Papesh, executive director of the Aossociation of Movement Disorder Advanced Practice Providers, recently told NeurobiologyLive. “Continuous subcutaneous apomorphine infusion already has a proven and established 30-year history in Europe, where it has helped deliver more consistent control of motor fluctuations for thousands of patients,” said Dr Rajesh Pahwa, professor of Neurology at the University of Kansas School of Medicine, and another trial investigator. "Today’s approval of Onapgo means patients in the US who are not responding well to their current treatment regimen, including levodopa, will now have the option of using a small and lightweight wearable device to deliver a continuous infusion without the need for an invasive surgical procedure," Pahwa added.

Get the Android app